Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
In the treatment of patients with early oligoarticular psoriatic arthritis (PsA), the use of apremilast yields substantial improvements in both clinical and patient-reported outcomes, as shown in the results of the phase IV FOREMOST study.
Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
01 Sep 2024
Tofacitinib safe, efficacious in ankylosing spondylitis regardless of baseline CRP
Tofacitinib demonstrates greater efficacy than placebo at week 12 in patients with ankylosing spondylitis (AS) regardless of their baseline C-reactive protein (CRP) levels, a study has shown.
Tofacitinib safe, efficacious in ankylosing spondylitis regardless of baseline CRP
31 Aug 2024
RA disease activity, provider preference linked to telehealth appropriateness
Telehealth appropriateness is significantly associated with provider preference, the current and previous encounter modality, and rheumatoid arthritis (RA) disease activity, but not with RA medications, patient demographics, and comorbid noninflammatory causes of joint pain, a study has shown.
RA disease activity, provider preference linked to telehealth appropriateness
30 Aug 2024
Circulating IL-17A predicts CVD in early RA
Circulating interleukin (IL)-17A in patients diagnosed with rheumatoid arthritis (RA) is associated with the incidence of cardiovascular disease (CVD), independent of traditional CVD risk factors and of erythrocyte sedimentation rate (ESR) at the time of diagnosis, suggests a study.
Circulating IL-17A predicts CVD in early RA
29 Aug 2024
PT-led on par with rheumatologist triage of joint pain referrals
A triage led by a physiotherapist (PT) performs as reliably as a rheumatologist triage of referrals for joint pain, with significantly fewer patients with inflammatory arthritis (IA) needing an in-clinic visit, a recent study has shown.
PT-led on par with rheumatologist triage of joint pain referrals
07 Aug 2024
Biosimilar DMARDs cost-effective vs leflunomide in RA patients after MTX failure
An economic evaluation study by the University of Hong Kong (HKU) found treatment with biosimilar disease-modifying antirheumatic drugs (DMARDs) to be cost-effective compared with leflunomide in patients with rheumatoid arthritis (RA) who failed initial treatment with methotrexate (MTX).